Clinical efficacy and safety of neoadjuvant chemotherapy with paclitaxel and cisplatin in combination with concurrent chemoradiotherapy for locally advanced cervical cancer: a systematic review and meta-analysis
Penpa Yeshe, Fang Li · 2024
Read Clinical efficacy and safety of neoadjuvant chemotherapy with paclitaxel and cisplatin in combination with concurrent chemoradiotherapy for locally advanced cervical cancer: a systematic review and meta-analysis by Penpa Yeshe, Fang Li (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11630013.txt.
Description
Penpa Yeshe and Fang Li pool past trials in a 2024 meta-analysis on care for advanced cervical cancer that stays in the pelvis. The standard care pairs chemo with radiation at the same time. The pair ask if adding chemo first, with the drugs paclitaxel and cisplatin, helps women live longer and stay free of the disease. They screened the past work and kept eight studies for the pooled sums.
Women who got the added chemo lived longer at two, three, and five years than women who got standard care alone. They also stayed free of the disease longer and had fuller shrinkage of the tumor. Rates of a return of the disease were lower. Side effects such as low blood counts were no worse than with standard care, the pooled data show.
Catalog record
| CREATOR | Penpa Yeshe, Fang Li |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |